Startseite Kongressberichte & Archiv Archiv 2016 58th Annual Meeting of the American Society of Hematology

58th ASH Annual Meeting & Exposition

The premier event in malignant & non-malignant hematology

December 3-6, 2016, San Diego, CA

LINKS TO WEBCASTS AT THE BOTTOM OF PAGE 

Conference website

Final Pogram & Abstracts

Read ASH News Daily 2016:

Saturday
Sunday
Monday
Tuesday

ASH News TV

Simultaneous Oral Sessions (links to program & abstracts)

ASH Press Release: Highly Anticipated Late-Breaking Abstracts Session to Feature Groundbreaking Scientific Data During 58th ASH Annual Meeting 

(SAN DIEGO, December 6, 2016)  — The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, will highlight the following novel studies in its late-breaking abstracts session today at the 58th ASH Annual Meeting and Exposition in San Diego: 

•    Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit
•    IKZF1 Gene Mutations Found to Increase Hereditary Risk for Acute Lymphocytic Leukemia in Children
•    Cancer Drug Ibrutinib Found Helpful in Treating Graft Versus Host Disease After Stem Cell Transplant
•    New Data Shed Light on Potential Advantages of Pacritinib for Patients with Myelofibrosis 
•    First Multicenter Trial Finds CAR T-Cell Immunotherapy Effective, Feasible for Hard-to-Treat Lymphoma